Certolizumab pegol (CDP870) for treatment of Crohn's disease [3]

Gastroenterology

Volumn 130, Issue 1, 2006, Pages 285-286

  Sisson, Guy ^a   Harris, Adam ^a  

^a KENT AND SUSSEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; PLACEBO;

CIGARETTE SMOKING; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; HUMAN; LETTER; PRIORITY JOURNAL; SMOKING CESSATION; SMOKING HABIT; TREATMENT OUTCOME;

EID: 30044445028     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2005.11.044     Document Type: Letter

References (4)

1. S. Schreiber, P. Rutgeerts, R.N. Fedorak A randomised, placebo-controlled trial of certolizumab Pegol (CDP870) for treatment of Crohn's disease Gastroenterology 129 2005 807 818
2. P.E. Lindberg, G. Jarnerot, B. Huitfelt Smoking in Crohn's disease effect on localisation and clinical course Gut 33 1992 779 782
3. J. Cosnes, F. Carbonnel, L. Beaugerie, Y. LeQuintrec, J. Gendre Effects of cigarette smoking on the long-term course of Crohn's disease Gastroenterology 110 1996 424 431
4. M.A. Parsi, J. Achkar, S. Richardson Predictors of response to infliximab in patients with Crohn's disease Gastroenterology 123 2002 707 713